// App-Quantinova.ai

586 : Pegaspargase Re-Challenge after Grade 2 Hypersensitivity Reaction in Childhood Acute Lymphoblastic Leukemia: Results from DFCI 16-001

Researchers

Presenter

  • Lynda M. Vrooman

Principal Investigators

  • Yael Flamand

  • Victoria Koch

  • Melissa A. Burns

  • Sarah M. Cronholm

  • Sarah K. Hunt

  • Peter D. Cole

  • Lisa M. Gennarini

  • Justine M. Kahn

  • Kara M. Kelly

  • Bruno Michon

  • Donna S. Neuberg

  • Andrew E. Place

  • Thai Hoa Tran

  • Jennifer J.G. Welch

  • Kristen E. Stevenson

  • Stephen E. Sallan

  • Lewis B. Silverman

Medical Centers

  • Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA

  • Department of Imaging, Dana-Farber Cancer Institute, Boston, MA

  • Cancer Institute of New Jersey, Rutgers University, New Brunswick, NJ.

  • The Children's Hospital at Montefiore, Bronx, NY

  • Pediatric Hematology/Oncology, Columbia University Medical Center, NYC, NY

  • Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY

  • Division of Rheumatology, Centre Hospitalier de l'Université Laval, Québec, QC, Canada

  • Department of Imaging, Dana-Farber Cancer Institute, Boston, MA

  • Centre Hospitalier Universitaire, Quebec, Canada

  • Division of Pediatric Hematology-Oncology, Hasbro Children's Hospital, Providence, RI

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

  • Serum amyloid A

Drug/Treatment

  • Diphenhydramine

  • Derma-Pax lotion

  • Hydrocortisone

  • Erwinase

  • Acetaminophen

  • Pegaspargase

  • Oncaspar

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved